KONGDY Health·16h agoWhy Your Manufacturer's Electronic Batch Record Is a Filing Cabinet With a Database Behind It…A paperless batch record or a manufacturing execution system is usually introduced to a buyer as a digital version of the paper process it…
KONGDY Health·1d agoWhy Your Regulatory Submission Written With AI Will Fail the First Time an Inspector Reads the…Every regulatory organisation has now had the conversation about artificial intelligence, and the conversation has settled into two…
KONGDY Health·2d agoWhy Your Manufacturer's Second Plant Is Not a Backup Site Until You Can Qualify a Lot From It…A second manufacturing site is usually presented to a buyer as an unqualified good: it removes the single-site dependency, it adds…
KONGDY Health·3d agoWhy Your Transdermal Patch Safety Stock Is a Liability Wearing a Security Uniform: Seven…Capacity that cannot be flexed has to be buffered instead, and inventory is the buffer most buyers reach for first. It is also the buffer…
KONGDY Health·6d agoWhy Your Transdermal Patch Capacity Promise Is a Nominal Rate and Not a Delivery Plan: Seven…Capacity in a transdermal programme is usually quoted as a number of units per year, and that number is almost always a piece of arithmetic…
KONGDY Health·Nov 12Why Your Transdermal Patch Continuity Plan Does Not Cover the Scenario That Ends Your Supply: Seven…A business continuity plan for a transdermal manufacturer is usually written as a document about the factory, and it is usually written for…
KONGDY Health·Nov 11Why Your Transdermal Patch Real-World Evidence Will Not Be Accepted Where You Need It: Seven…Real-world evidence is the most oversold and under-specified tool in a transdermal programme, because it is usually adopted as a hope…
KONGDY Health·Nov 10Why Your Transdermal Patch Label Update Will Reach One Market Eleven Weeks Before Another: Seven…A label change on a transdermal patch looks like the smallest regulatory event a programme will ever manage, because the product does not…
KONGDY Health·Nov 9Why Your Transdermal Patch PSUR Will Fail the Cumulative Test: Seven Specifications Every Buyer…The periodic safety update report is the document where a transdermal product’s cumulative safety experience has to be converted into a…
KONGDY Health·Nov 6Why Your Transdermal Patch Post-Marketing Surveillance Will Miss the Signal That Matters: Seven…Post-marketing surveillance is the phase of a transdermal product’s life where the evidence stops being generated deliberately and starts…